Evaluation of the kinetic properties of background parenchymal enhancement throughout the phases of the menstrual cycle.

PURPOSE To develop and apply a semiautomatic method of segmenting fibroglandular tissue to quantify magnetic resonance (MR) imaging contrast material-enhancement kinetics of breast background parenchyma (BP) and lesions throughout the phases of the menstrual cycle in women with benign and malignant lesions. MATERIALS AND METHODS The institutional review board approved this retrospective HIPAA-compliant study, and informed consent was waived. From December 2008 to August 2011, 58 premenopausal women who had undergone contrast material-enhanced MR imaging and MR imaging-guided biopsy were identified. The longest time from the start of the last known period was 34 days. One lesion per patient (37 benign and 21 malignant) was analyzed. The patient groups were stratified according to the week of the menstrual cycle when MR imaging was performed. A method based on principal component analysis (PCA) was applied for quantitative analysis of signal enhancement in the BP and lesions by using the percentage of slope and percentage of enhancement. Linear regression and the Mann-Whitney U test were used to assess the association between the kinetic parameters and the week of the menstrual cycle. RESULTS In the women with benign lesions, percentages of slope and enhancement for both BP and lesions during week 2 were significantly (P < .05) lower than those in week 4. Percentage of enhancement in the lesion in week 2 was lower than that in week 3 (P < .05). The MR images of women with malignant lesions showed no significant difference between the weeks for any of the parameters. There was a strong positive correlation between lesion and BP percentage of slope (r = 0.72) and between lesion and BP percentage of enhancement (r = 0.67) in the benign group. There was also a significant (P = .03) difference in lesion percentage of slope between the benign and malignant groups at week 2. CONCLUSION The PCA-based method can quantify contrast enhancement kinetics of BP semiautomatically, and kinetics of BP and lesions vary according to the week of the menstrual cycle in benign but not in malignant lesions.

[1]  M. Pike,et al.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.

[2]  H. Degani,et al.  Principal component analysis of breast DCE‐MRI adjusted with a model‐based method , 2009, Journal of magnetic resonance imaging : JMRI.

[3]  C. Maier,et al.  Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle , 2005, Breast Cancer Research.

[4]  Michael J Paldino,et al.  Fundamentals of quantitative dynamic contrast-enhanced MR imaging. , 2009, Magnetic resonance imaging clinics of North America.

[5]  J. Wolfe,et al.  Mammographic features and breast cancer risk: effects with time, age, and menopause status. , 1995, Journal of the National Cancer Institute.

[6]  Daniel B Kopans,et al.  Physiologic Changes in Breast Magnetic Resonance Imaging during the Menstrual Cycle: Perfusion Imaging, Signal Enhancement, and Influence of the T1 Relaxation Time of Breast Tissue , 2005, The breast journal.

[7]  Leon Axel,et al.  Combination of Compressed Sensing and Parallel Imaging for Highly-Accelerated 3 D First-Pass Cardiac Perfusion MRI , 2009 .

[8]  P. Unterberger,et al.  Cell Proliferation, Apoptosis, and Expression of Bcl-2 and Bax in Non-Lactating Human Breast Epithelium in Relation to the Menstrual Cycle and Reproductive History , 2004, Breast Cancer Research and Treatment.

[9]  D. Georgian-Smith,et al.  Controversies on the management of high-risk lesions at core biopsy from a radiology/pathology perspective. , 2010, Radiologic clinics of North America.

[10]  C. Claussen,et al.  Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. , 1997, Radiology.

[11]  R. Zeppa.  Vascular Response of the Breast to Estrogen1 , 1969 .

[12]  N. Boyd,et al.  Mammographic density and the risk and detection of breast cancer. , 2007, The New England journal of medicine.

[13]  Jennifer D. Brooks,et al.  Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI , 2012, European Radiology.

[14]  J. L. Hodges,et al.  Estimates of Location Based on Rank Tests , 1963 .

[15]  Jennifer D. Brooks,et al.  Impact of Tamoxifen on Amount of Fibroglandular Tissue, Background Parenchymal Enhancement, and Cysts on Breast Magnetic Resonance Imaging , 2012, The breast journal.

[16]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[17]  D. Heisey,et al.  The Abuse of Power , 2001 .

[18]  G. Ruxton,et al.  Confidence intervals are a more useful complement to nonsignificant tests than are power calculations , 2003 .

[19]  D. Bluemke,et al.  Dynamic contrast-enhanced MRI of the breast: quantitative method for kinetic curve type assessment. , 2009, AJR. American journal of roentgenology.

[20]  A. Miller,et al.  Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. , 1995, Journal of the National Cancer Institute.

[21]  M. Lux,et al.  Association of mammographic density with hormone receptors in invasive breast cancers: Results from a case‐only study , 2012, International journal of cancer.

[22]  Jennifer D. Brooks,et al.  Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. , 2012, Radiology.

[23]  F Merletti,et al.  Mammographic features of the breast and breast cancer risk. , 1982, American journal of epidemiology.

[24]  Xiaobing Fan,et al.  The diverse pathology and kinetics of mass, nonmass, and focus enhancement on MR imaging of the breast , 2011, Journal of magnetic resonance imaging : JMRI.

[25]  R. Casper,et al.  The effect of acute aromatase inhibition on breast parenchymal enhancement in magnetic resonance imaging: a prospective pilot clinical trial , 2012, Menopause.

[26]  Wendy B DeMartini,et al.  Background parenchymal enhancement on breast MRI: impact on diagnostic performance. , 2012, AJR. American journal of roentgenology.

[27]  Elizabeth A Morris,et al.  Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up. , 2011, AJR. American journal of roentgenology.

[28]  J. Halverson,et al.  The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  L. Chiazze,et al.  The length and variability of the human menstrual cycle. , 1968, JAMA.

[30]  R N Hoover,et al.  Mammographic densities and risk of breast cancer , 1991, Cancer.

[31]  G Lutterbey,et al.  Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. , 1997, Radiology.

[32]  S. Duffy,et al.  Mammographic parenchymal patterns and mode of detection: implications for the breast screening programme , 1998, Journal of medical screening.

[33]  Seema A. Khan,et al.  Morphological Changes in Breast Tissue with Menstrual Cycle , 2002, Modern Pathology.

[34]  E. Morris.  Diagnostic breast MR imaging: current status and future directions. , 2007, Radiologic clinics of North America.

[35]  J. Otten,et al.  Mammographic breast density and risk of breast cancer: Masking bias or causality? , 1998, European Journal of Epidemiology.

[36]  M. Schnall,et al.  Breast MR imaging in the diagnostic setting. , 2006, Magnetic resonance imaging clinics of North America.

[37]  Jennifer D. Brooks,et al.  Background parenchymal enhancement at breast MR imaging and breast cancer risk. , 2011, Radiology.

[38]  F. Vogel,et al.  The correlation of histologic changes in the human breast with the menstrual cycle. , 1981, The American journal of pathology.

[39]  E. Halpern,et al.  Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging--initial observations. , 2005, Radiology.

[40]  Erez Eyal,et al.  Model‐based and model‐free parametric analysis of breast dynamic‐contrast‐enhanced MRI , 2009, NMR in biomedicine.

[41]  Harry Quon,et al.  Transcytolemmal water exchange in pharmacokinetic analysis of dynamic contrast‐enhanced MRI data in squamous cell carcinoma of the head and neck , 2007, Journal of magnetic resonance imaging : JMRI.

[42]  J. Wolfe,et al.  Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. , 1987, AJR. American journal of roentgenology.

[43]  I Tocino,et al.  Follow-up of breast lesions diagnosed as benign with stereotactic core-needle biopsy: frequency of mammographic change and false-negative rate. , 1999, Radiology.

[44]  M. Meguid,et al.  Estrogen receptor expression in benign breast epithelium and breast cancer risk. , 1998, Journal of the National Cancer Institute.

[45]  David L. Page,et al.  Atypical hyperplastic lesions of the female breast. A long‐term follow‐up study , 1985, Cancer.

[46]  C. Kuhl,et al.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? , 1999, Radiology.

[47]  J Whitehead,et al.  Wolfe mammographic parenchymal patterns. A study of the masking hypothesis of Egan and Mosteller , 1985, Cancer.